Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR
- PMID: 33382182
- DOI: 10.1002/anie.202015628
Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR
Abstract
Tumor-derived exosomal proteins have emerged as promising biomarkers for cancer diagnosis, but the quantitation accuracy is hindered by large numbers of normal cell-derived exosomes. Herein, we developed a dual-target-specific aptamer recognition activated in situ connection system on exosome membrane combined with droplet digital PCR (ddPCR) (TRACER) for quantitation of tumor-derived exosomal PD-L1 (Exo-PD-L1 ). Leveraging the high binding affinity of aptamers, excellent selectivity of dual-aptamer recognition, and the high sensitivity of ddPCR, this method exhibits significant sensitivity and selectivity for tracing tumor-derived Exo-PD-L1 in a wash-free manner. Due to the excellent sensitivity, the level of tumor-derived Exo-PD-L1 detected by TRACER can distinguish cancer patients from healthy donors, and for the first time was identified as a more reliable tumor diagnostic marker than total Exo-PD-L1 . The TRACER strategy holds great potential for converting exosomes into reliable clinical indicators and exploring the biological functions of exosomes.
Keywords: aptamers; exosomes; immunotherapy; proximity ligation assay.
© 2020 Wiley-VCH GmbH.
Similar articles
-
Coupling Aptamer-based Protein Tagging with Metabolic Glycan Labeling for In Situ Visualization and Biological Function Study of Exosomal Protein-Specific Glycosylation.Angew Chem Int Ed Engl. 2021 Aug 9;60(33):18111-18115. doi: 10.1002/anie.202103696. Epub 2021 Jul 9. Angew Chem Int Ed Engl. 2021. PMID: 34043264
-
A simple, rapid and low-cost qPCR assay for evaluating the severity of exosomal PD-L1-mediated T cell exhaustion in blood samples.Chem Commun (Camb). 2022 Jan 18;58(6):831-834. doi: 10.1039/d1cc06496g. Chem Commun (Camb). 2022. PMID: 34931643
-
Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.Small Methods. 2022 Sep;6(9):e2200549. doi: 10.1002/smtd.202200549. Epub 2022 Jul 10. Small Methods. 2022. PMID: 35810463
-
The role of exosomal PD-L1 in tumor progression and immunotherapy.Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943-019-1074-3. Mol Cancer. 2019. PMID: 31647023 Free PMC article. Review.
-
The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.Cells. 2021 Nov 19;10(11):3247. doi: 10.3390/cells10113247. Cells. 2021. PMID: 34831468 Free PMC article. Review.
Cited by
-
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.Front Immunol. 2024 Apr 25;15:1395332. doi: 10.3389/fimmu.2024.1395332. eCollection 2024. Front Immunol. 2024. PMID: 38726017 Free PMC article. Review.
-
Portable Aptasensor Based on Parallel Rolling Circle Amplification for Tumor-Derived Exosomes Liquid Biopsy.Adv Sci (Weinh). 2024 Aug;11(32):e2403371. doi: 10.1002/advs.202403371. Epub 2024 Jun 26. Adv Sci (Weinh). 2024. PMID: 38923850 Free PMC article.
-
Simultaneous subset tracing and miRNA profiling of tumor-derived exosomes via dual-surface-protein orthogonal barcoding.Sci Adv. 2023 Oct 6;9(40):eadi1556. doi: 10.1126/sciadv.adi1556. Epub 2023 Oct 4. Sci Adv. 2023. PMID: 37792944 Free PMC article.
-
Future of Digital Assays to Resolve Clinical Heterogeneity of Single Extracellular Vesicles.ACS Nano. 2022 Aug 23;16(8):11619-11645. doi: 10.1021/acsnano.2c04337. Epub 2022 Jul 29. ACS Nano. 2022. PMID: 35904433 Free PMC article. Review.
-
From biogenesis to aptasensors: advancements in analysis for tumor-derived extracellular vesicles research.Theranostics. 2024 Jul 2;14(10):4161-4183. doi: 10.7150/thno.95885. eCollection 2024. Theranostics. 2024. PMID: 38994022 Free PMC article. Review.
References
-
- R. Kalluri, V. S. LeBleu, Science 2021, 367, eaau6977.
-
- G. Raposo, W. Stoorvogel, J. Cell Biol. 2013, 200, 373-383.
-
- R. Xu, A. Rai, M. Chen, W. Suwakulsiri, D. W. Greening, R. J. Simpson, Nat. Rev. Clin. Oncol. 2018, 15, 617-638.
-
- None
-
- C. Yang, P. D. Robbins, Clin. Dev. Immunol. 2011, 2011, 842849;
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials